ArticleJournal of medical genetics2018
Risk category system to identify pituitary adenoma patients with
Article in Journal of medical genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00461188 (Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review.Frontiers in endocrinology · 2019Pooled it
- Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement.Nature reviews. Endocrinology · 2026Review
- Clinical and Genetic Spectrum of Large AIP Deletions.Human mutation · 2026Article
- Germline genetic variants in young-onset sporadic pituitary macroadenomas: A multigene panel analysis.Journal of clinical & translational endocrinology · 2025Article
- Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas.The Journal of clinical endocrinology and metabolism · 2024Article
- Pituitary gigantism due to a novelEndocrine oncology (Bristol, England) · 2024Article
- Low frequency of AIP mutations in patients with young-onset sporadic pituitary macroadenomas.Journal of endocrinological investigation · 2023Article
- An update on, and genetics of refractory adenomas of childhood.Pituitary · 2023Review
- MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands.International journal of molecular sciences · 2022Review
- Apoplexy in sporadic pituitary adenomas: a single referral center experience andArchives of endocrinology and metabolism · 2021Article
- Review
- Pituitary microadenoma with hypopituitarism presenting as hyponatremia.BMJ case reports · 2021Article
- Genetics of Acromegaly and Gigantism.Journal of clinical medicine · 2021Review
- Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms.Endocrine reviews · 2020Review
- Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors.The Journal of clinical endocrinology and metabolism · 2020Observational
- Aggressive pituitary tumors in the young and elderly.Reviews in endocrine & metabolic disorders · 2020Review
- Potential markers of disease behavior in acromegaly and gigantism.Expert review of endocrinology & metabolism · 2020Review
- Acromegaly in the setting of Tatton-Brown-Rahman Syndrome.Pituitary · 2020Article
- Pituitary Metastatic Composite Tumors: A Case Report with Next-Generation Sequencing and Review of the Literature.Case reports in oncological medicine · 2020Article
- The Genetics of Pituitary Adenomas.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundPredictive tools to identify patients at risk for gene mutations related to pituitary adenomas are very helpful in clinical practice. We therefore aimed to develop and validate a reliable risk category system for aryl hydrocarbon receptor-interacting protein (
methodsAn international cohort of 2227 subjects were consecutively recruited between 2007 and 2016, including patients with pituitary adenomas (familial and sporadic) and their relatives. All probands (n=1429) were screened for
results1405 patients had a pituitary tumour, of which 43% had a positive family history, 55.5% had somatotrophinomas and 81.5% presented with macroadenoma. Overall, 134 patients had an
conclusionWe propose a user-friendly risk categorisation system that can reliably group patients into high-risk, moderate-risk and low-risk groups for the presence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.